Orgenesis Stock (NASDAQ:ORGS)
Previous Close
$1.10
52W Range
$0.87 - $10.80
50D Avg
$3.20
200D Avg
$5.41
Market Cap
$5.63M
Avg Vol (3M)
$34.78K
Beta
1.32
Div Yield
-
ORGS Company Profile
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.
ORGS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| TALS | Tourmaline Bio, Inc. |
| ONCR | Oncorus, Inc. |
| ACHL | Achilles Therapeutics plc |
| LIXT | Lixte Biotechnology Holdings, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| AVTE | Aerovate Therapeutics, Inc. |
| ACRV | Acrivon Therapeutics, Inc. Common Stock |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| ANTX | AN2 Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| TFFP | TFF Pharmaceuticals, Inc. |
| RZLT | Rezolute, Inc. |
| INDP | Indaptus Therapeutics, Inc. |
| NRBO | NeuroBo Pharmaceuticals, Inc. |
| ADAG | Adagene Inc. |
| TNGX | Tango Therapeutics, Inc. |
| ELYM | Eliem Therapeutics, Inc. |